Activation of STAT3 and survivin expression also confers resistance to chemotherapeutic agents (5-FU or cisplatin) in gastric cancer [123], hepatocellular carcinoma [124], NSCC [125] and ovarian cancer [104]. Here, BIRC5 is linked to ovarian cancer.